Concluding a busy year, three PHRI researchers participated in the Global CVCT Forum, held December 8-10 in Washington, DC.
Scientist Philip Joseph presented on the cardiovascular polypill’s role in reducing cardiovascular events, based on findings from PURE, TIPS-3 and HOPE-3. He also joined a panel on expanding the polypill concept across therapeutic areas.
Scientist William McIntyre delivered a presentation and contributed to a panel on atrial fibrillation and clinical challenges in stroke prevention, highlighting findings from ASSERT and ARTESiA.
Senior Scientist Harriette Van Spall presented on using AI innovations to optimize clinical trials, addressing challenges and ethical considerations, and spoke on academic trial leadership with a focus on data integrity and conflict-of-interest management. In a Late-Breaking Clinical Trial session, she shared findings from an International Delphi Consensus Project on post-discharge heart failure management in complex, real-world populations. Van Spall also participated in panels on electrophysiology, reporting trial results, and accelerating evidence translation through efficacy-implementation hybrid trials.
